Skip to Main content Skip to Navigation
Journal articles

The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?

Abstract : Spondylarthritis (SpA) is an inflammatory rheumatic disease associated with increased incidence of major adverse cardiovascular events (MACEs). Recently, Paramarta et al. proposed the use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis to target certain inflammatory pathways. However, Nilotinib, which is highly effective for the treatment of patients with chronic myeloid leukaemia (CML), is also associated with an increased risk of MACEs. The authors suggest that Nilotinib may be effective in peripheral SpA by modulating inflammation, but not in axial SpA. Considering the vascular toxicity of Nilotinib and the acceleration of atherosclerosis in SpA patients, we suggest taking MACEs as an end-point in future trials.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01680961
Contributor : Laurent Jonchère <>
Submitted on : Thursday, January 11, 2018 - 11:22:55 AM
Last modification on : Monday, January 20, 2020 - 2:51:19 PM

Links full text

Identifiers

Citation

Loukman Omarjee, Vincent Jaquinandi, Guillaume Mahe. The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?. Journal of Translational Medicine, BioMed Central, 2017, 15 (1), pp.255. ⟨10.1186/s12967-017-1334-1⟩. ⟨hal-01680961⟩

Share

Metrics

Record views

121